Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Barclays hires Birchenough as chairman of healthcare investment banking

Published 07/07/2023, 22:24
Updated 07/07/2023, 22:27
© Reuters. FILE PHOTO: The Barclays logo is seen in front of displayed stock graph in this illustration taken June 21, 2017. REUTERS/Dado Ruvic/Illustration/File Photo

By David Carnevali

NEW YORK (Reuters) - Barclays (LON:BARC) Plc has hired Jim Birchenough from Wells Fargo (NYSE:WFC) & Co as its chairman of global healthcare investment banking, a spokesperson for the British bank confirmed, after Reuters reported on the appointment on Friday.

Birchenough last served as vice chairman of biopharma investment banking at Wells Fargo. A Wells Fargo spokesperson declined to comment.

Birchenough, who will be based in San Francisco, had previously worked at Barclays as a research analyst covering biotech companies. He held similar roles at BMO Capital Markets and Lehman Brothers in the early part of his career.

In his new role, Birchenough will also lead Barclays' global biopharma investment banking unit alongside Alexis de Rosnay, who joined the bank last year and is taking on an expanded role in addition to his responsibilities as chairman of global healthcare investment banking.

Birchenough's addition is a boost to the bank's healthcare investment banking unit, which had been hit by the departure of its vice chairman Darren Campili who left for Wells Fargo earlier this year.

"Jim has a real track record and it's well known within the industry, both from his tenure as a banker and his tenure as a research analyst," said Richard Landgarten, global head of healthcare and real estate investment banking at Barclays.

More than two dozen U.S. investment bankers have left Barclays since January when it named two new global co-heads of investment banking. They are Cathal Deasy, former co-head of Credit Suisse (SIX:CSGN) Group AG investment banking and capital markets, and Taylor Wright, former co-head of Morgan Stanley (NYSE:MS) global capital markets.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.